Large meta-analyses on the effect of adjuvant chemotherapy (CT) in early breast cancer show that the relative risk reduction by chemotherapy is independent of classical clinicopathological factors such as estrogen receptor, tumor size, nodal status, degree of histological differentiation and age [12,13]. The gene discussed is ESR1; the disease is breast cancer.